NASDAQ:CRBU 3 November 2025

Off-the-Shelf CAR-T Triumph: Caribou’s Breakthrough Results Spark Stock Surge

Caribou Biosciences reported its off-the-shelf CAR-T therapy vispa-cel achieved a 64% complete remission rate in lymphoma, with 51% of patients cancer-free after one year. In multiple myeloma, CB-011 showed a 92% overall response rate. Shares of Caribou more than doubled after the Nov. 3 announcement. No graft-vs-host disease was observed, though one fatal toxicity occurred.

3 November 2025

Biotechnology·NASDAQ:CRBU·Stock Market

Par Petroleum Shares Rise 5.8% Amid Refining Rally and Crude Oil Gains
March 23, 2026, 5:16 AM EDT. Par Petroleum (PARR) surged 5.8% to $61.39 on strong volume, extending a 37.1% gain over four weeks. The stock rallied alongside U.S. refiners as WTI crude neared $100 per barrel amid geopolitical tensions around the Strait of Hormuz. The company, renamed Par Pacific Holdings, has climbed over 300% in the past year, supported by liquidity near $900 million, cost-efficient growth efforts, and a focus on renewables. Analysts expect Q2 earnings of $0.74 per share, up 178.7% year-over-year, with revenues around $1.69 billion. Earnings estimate revisions have increased 1.7% over 30 days, often signaling upward price pressure. Par Petroleum holds a Zacks Rank #3 (Hold) while industry peer Valvoline fell 0.2% with a similar rank.